Objective: To analyze the effect and advantages in analgesia and sedation of butorphanol tartrate combined with dexmedetomidine in severe cerebral hemorrhage for patients with mechanical ventilation. Methods: 120 pati...Objective: To analyze the effect and advantages in analgesia and sedation of butorphanol tartrate combined with dexmedetomidine in severe cerebral hemorrhage for patients with mechanical ventilation. Methods: 120 patients with severe cerebral hemorrhage requiring analgesia and sedation were randomly selected and divided into two groups: the control group (dexmedetomidine treatment group) and the test group (dexmedetomidine combined with butorphanol tartrate). Two groups of patients with different drugs were analyzed. Results: The average dose of dexmedetomidine (microgram) and the total adverse events (Times) in the test group were significantly lower than those in the control group within 48 hours (P < 0.05);The dose of Butorphanol in the test group was small, and the patients in the control group used other opioid analgesics to pump more significantly. Conclusion: Using butorphanol tartrate combined with dexmedetomidine can achieve the same sedative effect and enhance the analgesic effect as using dexmedetomidine alone with less dose of dexmedetomidine, and the clinical effect is significant. It also solves the problem that adverse reactions such as blood pressure change and bradycardia are easy to occur when using large dose of dexmedetomidine and the infusion speed is fast in clinical application, and significantly reduces the incidence of adverse reactions. It is worthy of clinical application.展开更多
文摘Objective: To analyze the effect and advantages in analgesia and sedation of butorphanol tartrate combined with dexmedetomidine in severe cerebral hemorrhage for patients with mechanical ventilation. Methods: 120 patients with severe cerebral hemorrhage requiring analgesia and sedation were randomly selected and divided into two groups: the control group (dexmedetomidine treatment group) and the test group (dexmedetomidine combined with butorphanol tartrate). Two groups of patients with different drugs were analyzed. Results: The average dose of dexmedetomidine (microgram) and the total adverse events (Times) in the test group were significantly lower than those in the control group within 48 hours (P < 0.05);The dose of Butorphanol in the test group was small, and the patients in the control group used other opioid analgesics to pump more significantly. Conclusion: Using butorphanol tartrate combined with dexmedetomidine can achieve the same sedative effect and enhance the analgesic effect as using dexmedetomidine alone with less dose of dexmedetomidine, and the clinical effect is significant. It also solves the problem that adverse reactions such as blood pressure change and bradycardia are easy to occur when using large dose of dexmedetomidine and the infusion speed is fast in clinical application, and significantly reduces the incidence of adverse reactions. It is worthy of clinical application.
